Deep venous thrombosis after percutaneous insertion of vena caval filters  by Blebea, John et al.
Vena caval filters have been demonstrated to be
effective in the long-term prevention of pulmonary
embolization (PE). The incidence of PE with the
Greenfield filter has been reported to be only 3% in
patients followed for more than 20 years, and caval
patency is maintained in more than 95% of the
patients.1,2 The introduction of smaller diameter
delivery systems has made possible the percutaneous
placement of these filters. With progressive diminu-
tion in their size and greater ease of insertion, there
have been calls for their increased use, especially pro-
phylactically in trauma patients at high risk.3 A
recent multicenter study, however, has questioned
the overall clinical efficacy of vena caval filters
because of the increased subsequent development of
deep venous thrombosis (DVT) in the lower
extremities.4 This development was presumed to be
partially the result of thrombosis initiated at the per-
cutaneous insertion site. We reviewed our experi-
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Purpose: A large multicenter study has recently questioned the overall clinical efficacy of
vena caval filters, especially when inserted prophylactically, because of the subsequent
development of deep venous thrombosis (DVT) at the insertion site. We examined the
incidence of this complication with newer, smaller diameter percutaneous devices.
Methods: We reviewed our vascular surgery and interventional radiology clinical registries
to identify patients in whom a femoral percutaneous vena caval filter had been placed
from 1993 to 1998. This list was cross referenced with patients who had undergone lower
extremity venous ultrasound scan examinations for the diagnosis of DVT in the vascular
laboratory within a 60-day period before and after the insertion of the filter device.
Results: A total of 35 patients during this 5-year period had timely follow-up venous
duplex scan studies performed. The indications for filter placement were DVT in 16
patients (46%), pulmonary embolus in 13 patients (37%), DVT and pulmonary embolus
in three patients (9%), and prophylactically in three patients (9%) at high risk for throm-
boembolization. Of the patients with documented thromboembolic events, 91% (29 of
32) had contraindications to anticoagulation therapy, and the remaining 9% (3 of 32) rep-
resented failure of anticoagulation therapy. A Greenfield filter was used in 13 patients
(37%), a Simon Nitinol filter was used in 11 patients (31%), and a VenaTech filter was
used in nine patients (26%). The other two patients (6%) had a Bird’s Nest filter insert-
ed. At a mean follow-up period of 12 ± 2 days (median, 6 days), there was a 40% (14 of
35) incidence of proximal DVT in venous segments without evidence of thrombus before
filter insertion. The majority (71%; 10 of 14) occurred in the common femoral vein, with
three located in the superficial femoral vein and one in the external iliac vein. The lowest
incidence of DVT was seen with the Greenfield and Bird’s Nest filters as compared with
the smaller Simon Nitinol and VenaTech filters (20% vs 55%; P < .05). The highest inci-
dence of thrombosis occurred in patients with pre-insertion pulmonary emboli (50%; 8
of 16) as compared with those patients with DVT (38%; 6 of 16) and prophylactic inser-
tion (0%; 0 of 3). However, the subgroups were too small to attain statistical significance.
Conclusion: There is a continuing and significant incidence of new DVT development
ipsilateral to the percutaneous femoral insertion site of vena caval filters. The smaller
diameter filters are not associated with a lower incidence of femoral thrombosis. (J Vasc
Surg 1999;30:821-9.)
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ence with these filters to examine and compare the
incidence of this complication with the newer, small-
er diameter percutaneous devices.
PATIENTS AND METHODS
All the vena caval filter devices inserted at the
Milton S. Hershey Medical Center of the Penn State
Geisinger Health System are inserted either by 
members of the Sections of Vascular Surgery or Inter-
ventional Cardiovascular Radiology. We reviewed the
computerized patient registries of these two clinical
services to identify all patients in whom a femoral per-
cutaneous vena caval filter had been placed between
1993 to 1998. This list then was cross referenced with
the records of patients who had undergone lower
extremity venous duplex ultrasound scan examinations
for the diagnosis of DVT in the vascular laboratory
within a 60-day period before and after the insertion
of the filter device. Those patients who were identified
to have fulfilled these requirements form the basis of
this report.
The selection of a particular vena caval filter
device for insertion was made on the basis of the
personal preferences of the physician who performed
the procedure. Vascular surgeons preferentially used
the Greenfield stainless steel, over-the-wire filter
(Meditech, Boston Scientific, Watertown, Mass).
When the vena cava size exceeded 28 mm in diame-
ter, a Bird’s Nest filter (Cook Inc, Bloomington,
Ind) was used. The other devices used included the
VenaTech LGM (B Braun/VenaTech, Evanston, Ill)
and the Simon Nitinol filter (Bard Radiology,
Covington, Ga). Inferior vena caval angiography was
performed in all patients before filter insertion to
ascertain caval patency, diameter, and renal vein
location. It was surgical protocol to obtain a follow-
up duplex ultrasound scan of the lower extremities
approximately 1 week after the procedure. Follow-
up studies were not routinely obtained by the radio-
logic service. Details of filter placement were
obtained from surgical operative notes and interven-
tional radiology procedure notes. The indication for
the procedure, the type of filter, the introducer size,
the route of insertion, and complications during the
procedure were recorded. The duration of sheath
placement and the extent and duration of manual
compression after sheath removal were not record-
ed. The computerized hospital laboratory informa-
tion system (Powerchart, Cerner Corp, Kansas City,
Mo) was used to examine the prothrombin time, the
international normalized ratio, and the activated
partial thromboplastin times for the 2 days after the
insertion of the filter and on the day of the duplex
scan follow-up examination as an indication of the
anticoagulation status of the patients.
The duplex ultrasound scan examination records
were reviewed for each patient. The indications for
the examination, the presence and location of intra-
luminal thrombus, the characteristics of venous flow,
distal augmentation, and compressibility of vessel
walls with ultrasound scan probe compression were
recorded for each venous segment from the external
iliac vein to the tibial vessels.
The data were entered onto a spreadsheet (Excel
95, Microsoft, Redmond, Wash). The results are
expressed as the mean ± the standard error of the
mean. Statistical analysis was performed with the
SigmaStat statistical program (Jandel Scientific, San
Rafael, Calif). The Mann-Whitney rank sum test or the
Student t test were used to compare continuous data.
Either the Fischer exact test or the c 2 test were used
for dichotomous data. A two-tailed P value of less than
.05 was considered to be statistically significant.
RESULTS
During the 5-year time period from November
27, 1993, to December 31, 1998, there were a total
of 35 patients who fulfilled the inclusion criteria for
this study. This represented 13% of all the 265 vena
caval filters that were inserted during this time peri-
od. There were 23 male and 12 female patients. The
mean age was 59 ± 3 years, with a range of 17 to 89
years and a median age of 60 years. Sixteen patients
(46%) had proximal DVT (popliteal or more proxi-
mal veins), 13 patients (37%) had PE, three patients
(9%) had both DVT and PE, and the remaining
three patients (9%) were at high risk for throm-
boembolization. Of those patients with pre-inser-
tion DVT, two thirds had DVT in the left leg. Half
of the thrombi were located in the superficial
femoral-popliteal venous segments (Table I). None
of the thrombi were located in the common femoral
or external iliac veins on the side of percutaneous
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Table I. Pre-insertion deep venous thrombosis
location
Vein Right Left No.
External iliac 1 2 3 (6%)
Common femoral 2 3 5 (11%)
Superficial femoral 2 9 11 (23%)
Popliteal 4 8 12 (26%)
Calf 5 6 11 (23%)
Superficial/GSV 2 3 5 (11%)
Total 16 (34%) 31 (66%) 47 (100%)
GSV, Greater saphenous vein.
vena cava filter insertion. One patient had DVT in
the superficial femoral vein, and three patients had
popliteal venous involvement ipsilateral to the caval
filter insertion site.
The most frequent indication for the placement
of a vena caval filter was a contraindication to anti-
coagulation therapy in 29 patients, six of whom had
had bleeding complications while undergoing such
therapy (Table II). Anticoagulation therapy failure
with warfarin was seen in three patients. These
included two episodes of PE and one extension of
DVT while undergoing warfarin therapy for proxi-
mal DVT. Prophylactic vena cava interruption was
performed in the other three patients. One patient
had a distant history of PE and was pending cra-
niotomy for a glioblastoma, another had a subdural
hematoma after trauma and was pending a hip
replacement for an associated fracture, and the third
patient had a proximal thrombus of the greater
saphenous vein and was at continuing high throm-
boembolic risk because of traumatic head and pelvic
injuries and was immobilized in bed. The mean time
from the initial duplex scan diagnosis of DVT and
vena caval interruption was 1.3 ± 0.5 days, with a
range of 0 to 17 days and a median of 0 days.
Of the filters that were inserted, 28 (80%) were
inserted by fellowship-trained interventional radiolo-
gists and the remaining seven (20%) were inserted by
vascular surgeons. The surgical service inserted only
the Greenfield stainless steel over-the-wire filters, and
the radiologists inserted a variety of others (Table III).
They were preferentially inserted via the right com-
mon femoral vein (31; 89%) unless monitoring
catheters or recent trauma precluded this choice of
insertion site (n = 3) or venous cannulation was tech-
nically unsuccessful, in which case the contralateral left
femoral vein was used. The only periprocedural com-
plications that were encountered were three initial
incidental insertions of the 18-gauge finder needles
into the femoral artery. These needles were with-
drawn, and the vein thereafter successfully cannulated
without untoward effects. All the attempts at place-
ment of the filter were successful, and none were
noted to be malpositioned. Postinsertion anticoagula-
tion therapy was used in one patient with a Bird’s
Nest filter, in two patients with Greenfield filters, in
four with Simon Nitinol filters, and in four with
VenaTech filters.
The mean time from filter insertion to follow-up
venous duplex scan examination was 12.0 ± 2.4
days, with a range of 0 to 50 days and a median of 6
days. There were a total of 14 patients with new
proximal DVT ipsilateral to the filter insertion site,
which was not present on the pre-insertion duplex
scan study, for an overall incidence rate of 40%. The
majority of thrombi (71%; 10 of 14) occurred in the
common femoral vein. Most patients also had exten-
sion of thrombus either distally into the superficial
femoral and popliteal veins or proximally into the
external iliac vein (Table IV). Six patients had asso-
ciated thrombosis of the greater saphenous vein. Of
the 39 involved venous segments, 85% had occlusive
thrombus and the remainder, mostly in the common
femoral and external iliac veins, had non-occlusive
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Table II. Indications for vena cava filter 
No. of patients
Contraindications to anticoagulation therapy 29 (83%)
Bleeding with anticoagulation therapy 6
Thrombocytopenia 4
Recent trauma/surgery 3
Pre-operative 3
Bleeding before anticoagulation therapy 2
Metastatic carcinoma 2
Warfarin failure 3 (9%)
Prophylaxis 3 (9%)
TOTAL 35
Table IV. Deep venous thrombosis after vena
caval filter insertion 
Involved veins No. of patients
EIV only 1 (7%)
EIV and CFV 1 (7%)
EIV/CFV/SFV/popliteal 4 (29%)
CFV/SFV/popliteal 5 (36%)
SFV and popliteal 2 (14%)
SFV only 1 (7%)
TOTAL 14 (100%)
EIV, External iliac vein; CFV, common femoral vein; SFV, super-
ficial femoral vein.
Table III. Vena cava filters 
Diameter (F)
Filter type No. of filters Metal type Filter Sheath 
Greenfield 13 (37%)
Stainless steel 11 Stainless steel 12 15.6
Titanium 2 Titanium 12 14.3
Simon Nitinol 11 (31%) Nickel-titanium 7 9.0
VenaTech 9 (26%) Phynox 10 12.9
Bird’s Nest 2 (6%) Stainless steel 11 14.0
TOTAL 35
Diameters listed are outer diameters of the filters and sheaths.
DVT (Table V). There were no differences between
the occlusive and non-occlusive groups in terms of
postprocedural anticoagulation therapy or time
interval for follow-up duplex scan evaluation.
Three of the 14 patients with postinsertion DVT
had had either an ipsilateral superficial femoral (one
patient) or popliteal vein (two patients) thrombosis
before filter placement. These patients subsequently
had common femoral (n = 1), superficial and com-
mon femoral (n = 1), and superficial/common
femoral/external iliac venous thrombosis (n = 1)
develop. If these patients were excluded from con-
sideration, the completely de novo thrombosis rate
would be 31%. All of the other patients had only
contralateral DVT present before caval filter place-
ment. The total number of patients with proximal
DVT, on either side, was 24 (69%) as compared with
19 (54%) before intervention. The bilateral proximal
DVT rate increased from 5% (1 of 19) to 53% (11 of
24) after filter insertion (P < .01). The overall seg-
mental distribution of thrombi changed accordingly,
reflecting a more proximal preponderance of DVT
within the external iliac and common femoral veins
and a greater number in the right lower extremity
(Table VI).
There was a significant correlation between the
incidence of insertion side thrombosis and the type of
vena cava filter. Of the filter types that had more than
two inserted, the Greenfield filter had the smallest
incidence of thrombosis and the Simon Nitinol had
the highest incidence (Table VII). Interestingly, the
two larger filters with a diameter of greater than 10F
(Greenfield and Bird’s Nest) had a significantly lower
rate of thrombosis than did the smaller diameter filters
(Simon Nitinol and VenaTech; 20% vs 55%; P < .05).
Patients referred to the vascular laboratory after inser-
tion of a caval filter because of ipsilateral lower
extremity symptoms had a significantly higher proba-
bility of having DVT on that side (86%; 6 of 7) as
compared with patients with contralateral symptoms
(25%; 2 of 8; P < .05) or patients who were asympto-
matic and returning for a routine follow-up examina-
tion (8%; 1 of 12; P < .005). Patients whose indica-
tions for a duplex scan examination were not clearly
specified in the laboratory records and who may have
possibly been symptomatic also had a high incidence
rate of DVT (63%; 5 of 8).
Although the highest incidence of thrombosis
occurred in patients with pre-insertion PE (50%; 8
of 16) as compared with those with DVT (38%; 6 of
16) and prophylactic insertion (0%; 0 of 3), the sub-
groups were too small to attain statistical signifi-
cance. The follow-up times were longer for the
patients who were found to have DVT as compared
with those patients who did not (16 ± 4 versus 9 ±
2 days), although this did not reach statistical signif-
icance (P = .07). Three of four patients with carci-
noma had insertion site thrombosis, all having
undergone treatment with a Greenfield filter. There
were no significant differences in the use of postop-
erative anticoagulation therapy among the filter
types. There were also no differences, either just
after filter insertion or at the time of later duplex
scan examination, in the prothrombin time, the
international normalized ratio, or the partial throm-
boplastin time between the patients who had postin-
sertion DVT develop and those who did not.
JOURNAL OF VASCULAR SURGERY
824 Blebea et al November 1999
Table VII. Filter type and insertion site thrombosis
No. of No. of patients
Filter type patients with DVT Percent
Greenfield 13 3 23%
Stainless steel 11 2 18%
Titanium 2 1 50%
Simon Nitinol 11 7 64%
VenaTech 9 4 44%
Bird’s Nest 2 0 0%
TOTAL 35 14 40%
DVT, Deep venous thrombosis.
Table VI. Deep venous thrombosis location after
insertion
Vein Right Left No. of veins
External iliac 6 8 14 (11%)
Common femoral 12 12 24 (19%)
Superficial femoral 13 18 31 (25%)
Popliteal 12 13 25 (20%)
Calf 10 7 17 (14%)
Superficial/GSV 7 7 14 (11%)
Total (%) 60 (48%) 65 (52%) 125 (100%)
GSV, Greater saphenous vein.
Table V. Ipsilateral deep venous thrombosis after
filter insertion 
Vein segments No. of veins Occlusive Non-occlusive
External iliac 6 4 2
Common femoral 10 7 3
Superficial femoral 12 11 1
Popliteal 11 11 0
Total 39 33 (85%) 6 (15%)
DISCUSSION
Venous thromboembolic disease, manifested as
either DVT or PE, is a significant clinical problem.
Together, DVT and PE are responsible for more than
600,000 hospitalizations and 150,000 deaths year-
ly.5-9 Patients with PE have a 3-month mortality rate
of 18%, and those with only DVT have a 1-year mor-
tality rate of 21%.10 Inferior vena caval filters are as
much as 97% effective for the prevention of PE and
maintain a 95% caval patency rate.1,2,11 According to
industry sources, approximately 40,000 filters are
inserted annually in the United States.12 The accept-
ed indications for filter placement include contraindi-
cations to conventional anticoagulation therapy in
patients with either DVT or PE, extension of DVT or
recurrent PE despite adequate anticoagulation thera-
py, complications of anticoagulation treatment, and
prophylactic placement in patients at high risk for
thromboembolic disease.13 Our indications for filter
insertion were similar to those reported by others,
with more than three quarters of our patients under-
going treatment because of contraindications to anti-
coagulation therapy and only 9% prophylactically
because they were at high risk for PE (Table I).12,14-16
Similarly, about half of our patients had DVT (Table
II), and most of the remaining patients had PE,
either alone or in combination with DVT.
Within the past decade, it has been proposed
that prophylactic vena caval interruption be more
widely used, especially in trauma patients, both
because of their high risk for thromboembolic com-
plications and because anticoagulation therapy is fre-
quently contraindicated in such circumstances.
Khansarinia et al,3 along with others, found that the
Greenfield filter effectively prevented both PE and
PE-related deaths in trauma patients at high risk and
recommended its use.13,17 However, a recent study
by Decousus et al4 has questioned the long-term
benefits of vena caval filters. In a multicenter trial of
400 patients with proximal DVT, half were random-
ized to receive heparin anticoagulation therapy and
the others underwent vena caval interruption with a
variety of filters. Although the patients who had fil-
ters implanted had an initial reduction in PE (1.1%
as compared with 4.8%), this difference lost statisti-
cal significance at 2 years (3.4% vs 6.3%) and was off-
set by a higher recurrence rate of DVT in the filter
group (20.8% vs 11.6%; P = .02). On this basis, the
investigators cautioned against the use of caval filters
in this patient population. The authors mentioned
that this increase in DVT recurrence could have
been related to thrombosis at the filter insertion site,
but such specific information was not available from
their report. If, as in our study, the DVTs that were
seen within the first 3 months were associated with
venous thrombosis at the filter insertion site, their
prevention would have eliminated the long-term
DVT disadvantage ascribed to the caval filters (15%
vs 12%; P = .42) and maintained beneficial protec-
tion against PE.
The initial experience with the percutaneous
placement of caval filters showed a high incidence of
insertion site thrombosis. Pais et al,18 in a series of
24 patients with the original 24F Greenfield filter
(29.5F sheath outer diameter), documented by
ultrasound common femoral vein thrombosis related
to filter placement in 33% of patients at a mean of 14
days, although less than one third of the patients
were symptomatic. In another series, with venogra-
phy at follow-up of 5 to 8 days, 41% of 17 patients
had thrombosis of the common femoral vein, half of
whom were symptomatic.19 Mewissen et al20 had a
19% incidence rate of thrombosis in 47 patients at
24 hours after insertion of the Greenfield filter,
although less than half of the patients were sympto-
matic during the first month. Dorfman et al21 found
14% to have complete thrombosis and another 19%
to have venous “abnormalities” noted on ultrasound
scanning. This early experience documented both
the high incidence of insertion site thrombosis and
that more than half of such patients were asympto-
matic. It was hoped that, with the introduction of
smaller carrier systems and other technical innova-
tions, the occurrence of such DVTs would dimin-
ish.20
This goal does not, however, seem to have been
achieved. Although symptomatic insertion-site DVT
was reported in only 2% of almost 1436 patients from
collected series with the newer filters, few of these
reports reflect regular surveillance to detect subclini-
cal asymptomatic occurrences.2 In the initial series
from Greenfield et al15 that evaluated the newer tita-
nium filter with a much smaller, 14F outside diameter
sheath, 30 patients were seen at a mean of 5 months
after filter insertion. DVT was documented in only
two patients (7%) at the insertion site, although it is
unclear whether all the patients underwent a com-
plete duplex scan examination of the insertion site
regardless of symptoms. Patton et al17 documented a
9% incidence rate (3 of 33) of symptomatic in-hospi-
tal insertion site thrombosis when the titanium
Greenfield was placed prophylactically in trauma
patients at high risk. Harris et al22 found an 18% inci-
dence rate (4 of 22) of phlegmasia cerulea dolens in
patients who had the titanium filter placed via the
femoral approach at a mean of 5 days after filter inser-
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tion. When the patients were followed with ultra-
sound scan examination independent of symptoms,
Molgaard et al14 found a 38% incidence rate (5 of 13)
of either occlusive or non-occlusive thrombus in the
common femoral vein, and Ferris et al16 found a 30%
incidence rate (6 of 20) of thrombosis in patients who
were symptomatic. These results are consistent with
our experience and a 23% incidence rate of DVT ipsi-
lateral to Greenfield filter insertion at a mean follow-
up period of 7 days (Table VII).
We had no thrombosis with the next largest fil-
ter, the Bird’s Nest, although with only two patients
in this series no statistical comparisons can be made.
Other investigators, however, have reported an inci-
dence of DVT similar to that of the Greenfield filter.
Ferris et al16 found a 17% incidence rate (7 of 42) of
thrombosis in patients who were symptomatic. With
routine follow-up ultrasound scanning, Molgaard et
al14 noted a 33% incidence rate (4 of 12) of DVT,
and Hicks et al23 documented 21% (10 of 48) of
patients to have either complete or partial occlusion
at the insertion site within 11 days.
The two smallest filters in our experience had a
worse combined outcome as compared with the larg-
er Greenfield and Bird’s Nest filters (55% vs 20%). We
found a 44% ipsilateral DVT rate with the VenaTech
filter. Although Millward et al24 reported only a 6%
thrombosis rate, their report does not specify whether
all patients were studied with duplex ultrasound scan
after insertion, with what frequency they were fol-
lowed, or when the thrombosis was discovered. More
consistent with our findings, Ferris et al16 noted a
32% incidence rate (8 of 25) of thrombosis in patients
who were symptomatic, and Molgaard et al14 report-
ed a 34% incidence rate (12 of 35) on routine ultra-
sound scan follow-up examination. Similarly, Murphy
et al25 documented a 23% incidence rate (8 of 35) of
thrombosis, detected with either duplex ultrasound
scanning or venography. These results were not sig-
nificantly different from what they had found with the
original Greenfield filter.21
Although by far the smallest in both the diameter
of the filter and the outer diameter of the sheath, the
Simon Nitinol 7F filter had a 64% incidence rate of
DVT ipsilateral to the filter insertion site. In two small
series, one series showed symptomatic DVT in two of
16 patients (13%) who had filters placed through the
femoral approach,26 and another series found an 11%
incidence rate (1 of 9) in patients who were sympto-
matic.16 In the original series from Simon et al,27
however, when duplex ultrasound scanning was
prospectively performed in 18 patients after nitinol fil-
ter placement, insertion site thrombus was found in
five (28%) of these patients. We have found no other
reports that examined insertion site thrombosis with
the nitinol filter. At the very least, although we also
report on a small series of patients, it does not appear
that its small size has been associated with a decreased
risk of subsequent insertion site thrombosis.
Recurrent DVT at the insertion site may be
caused by endothelial and intimal injury from the
percutaneous placement of the filters followed by
thrombus formation during relative venous stasis
while extrinsic compression is applied. This theory is
supported by the finding that most of the thrombi
that develop are located at the most frequent sheath
entry site, the common femoral vein, with both
proximal and distal thrombus extension possible
(Table IV). With proximal venography, Kantor et
al19 showed all these early thrombi to be located at
the common femoral and iliac veins. Local intimal
injury does not necessarily lead to complete throm-
bosis of the involved vein. Non-occlusive thrombi
may develop, as was seen in 15% of our patients
(Table V), which was consistent with the findings of
others.14 The hope that less intimal injury, and asso-
ciated thrombotic complications, would occur with
smaller delivery systems warrants continuing obser-
vation. However, the high rate of thrombosis even
with the smallest Simon Nitinol filter suggests that
this alone is not the only important variable.
Other likely contributing factors are the hyperco-
agulable states that are invariably present in these
patients and that are the underlying pathophysiolog-
ic derangements requiring the placement of vena
caval filters. It is prudent to continue anticoagulation
therapy after filter insertion in patients who do not
have a definite contraindication. All of the patients in
the study from Harris et al22 in whom phlegmasia
developed after vena caval filters had not been under-
going anticoagulation therapy, suggesting to these
investigators that anticoagulant therapy should be
continued if at all possible.22 Most of the patients in
the study from Kantor et al19 with later thrombosis
(5 of 7) did not undergo anticoagulation therapy
after filter insertion. Patients with an underlying
malignant disease may be at higher risk for later inser-
tion site thrombosis.14 Although previous investiga-
tors have failed to establish a significant difference in
the incidence of insertion site thrombosis between
patients with and without postprocedural anticoagu-
lation therapy, the ability to achieve statistical signifi-
cance is limited by the small number of patients at
individual institutions. In our examination of the sur-
rogate markers for anticoagulation therapy, the labo-
ratory coagulation profiles, we similarly could not
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establish a relationship between anticoagulation ther-
apy and later DVT development, although our study
also suffered from the limitation of a small number of
patients in each group. Nonetheless, we recommend
that whenever possible anticoagulation therapy be
continued both to control the underlying prothrom-
botic state and to decrease the prevalence of later
insertion site thrombosis.
Along with the systemic hypercoagulable state,
local venous conditions may also predispose to later
insertion site thrombosis. Caval occlusion could
diminish venous flow and increase distal venous
pressure, leading to a higher incidence of lower
extremity DVT. The presence of proximal vein par-
tial thrombus, either in the iliac or vena cava, or the
extrinsic compression of these veins have been asso-
ciated with a higher incidence of later insertion site
thrombosis.14 For this reason, either the contralater-
al femoral vein or a jugular approach should be used
when non-occlusive thrombus is found in the ipsi-
lateral iliac vein or vena cava, respectively. Although
other investigators have espoused a contrary view,20
the presence of distal thrombus in the superficial
femoral or popliteal veins may also predispose to
later DVT development. In three of our patients,
thrombi in these segments extended to involve the
common femoral vein after filter insertion.
Therefore, although not precluding the safe techni-
cal insertion of the filter through the femoral
approach, consideration should be given to an alter-
native access site in these situations. The right com-
mon femoral vein is technically easier to use for
right-handed individuals and is a straighter venous
segment than the left. Mewissen et al20 found the
left femoral vein to be associated with a higher mor-
bidity and recommended that the right side be pref-
erentially used. Molgaard et al14 found no significant
differences in insertion site thrombosis between the
right and left common femoral veins. With the pre-
sent smaller diameter and more flexible filters, the
left femoral approach is acceptable if needed because
of other considerations.
Almost all of the present literature that deals with
insertion site thrombosis has described this as a com-
plication of the femoral approach. The original
insertion site of the Kimray-Greenfield filter was via
the jugular approach.28 This route did not attain
popularity because of the risks of pneumothorax and
inadvertent carotid arterial puncture associated with
that site. However, because of the puncture-site
complications of the femoral approach, Kantor et
al19 have suggested the jugular approach be prefer-
entially be used in patients with a long life expectan-
cy. Similarly, to diminish the long-term morbidity of
venous insufficiency, Greenfield29 has suggested the
jugular route as possibly the preferred technique in
young trauma patients. To prevent the later devel-
opment of phlegmasia cerulea dolens in patients
who require vena caval interruption and cannot
undergo anticoagulant therapy, Harris et al22 rec-
ommended the consideration of the jugular access
site as a better alternative. Crochet et al30 routinely
prefer the right internal jugular vein for all caval fil-
ters. There is currently not enough information con-
cerning insertion site thrombosis of the internal
jugular vein to definitively recommend it as the pre-
ferred route for vena caval filter placement over the
femoral vein. It is advantageous in a number of cir-
cumstances, however. A prospective randomized
trial that would compare the two sites would be
worthwhile.
CONCLUSION
There is a continuing and significant incidence of
new DVT development ipsilateral to the percutaneous
femoral insertion site of vena caval filters. The risk of
insertion site thrombosis has not been eliminated with
the use of the smaller diameter filters and sheaths. The
higher thrombosis rate seen in our experience with
the smaller filters suggests that other variables beyond
filter size are important in the later development of
DVT. Anticoagulation therapy should be continued
after vena caval filter insertion unless definite and con-
tinuing contraindications exist to prevent its use.
Partial venous thrombosis proximal or distal to the
common femoral vein increases the risk of postinser-
tion DVT. The internal jugular vein may be a better
access site for vena caval filter insertion.
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Dr Lazar J. Greenfield (Ann Arbor, Mich). Congrat-
ulations to Dr Blebea and his associates on what I believe is a
timely study. I also want to express my thanks for the opportu-
nity to review their manuscript.
The problem of recurrent DVT after filter placement
was brought into a high level of concern recently by the
report of Decousas, as mentioned by the authors, and this
has been widely accepted despite serious flaws in the
design and analysis of their filter patient population. As a
result, many physicians now are afraid to discontinue anti-
coagulant therapy long term for fear of recurrent venous
thrombosis in patients with filters. Dr Blebea and his col-
leagues have reviewed their experience with patients who
have received filters inserted by either surgeons or radiol-
ogists during a 5-year period and who had follow-up
duplex scan examinations. Unfortunately, only 13% of
their filter patients fulfilled the entry criteria. So, my first
question is whether this group was truly representative of
the entire population or whether there is potential adverse
selection of symptomatic patients who were referred for
duplex scan study. It is clear that the surgeons were rou-
tinely performing duplex scan follow-up examinations 1
week after insertion, but because only 20% of the inser-
tions, or seven patients, had filters placed by surgeons, the
largest number were in fact treated by radiologists and
their method of follow-up examination is not stated.
One of the fundamental problems in assessing insertion
site venous thrombosis is the lack of definition of the extent
of thrombosis found. The variables affecting this include the
size of the vein puncture, the duration of sheath placement,
and the extent of manual compression on the vein after the
sheath is removed. Do the authors have any idea of how
these variables might have affected their results? The authors
did indicate that 85% of the thrombi were occlusive and 15%
were non-occlusive. The obvious question is whether there
were any differences in the two groups, such as the protocol
DISCUSSION
for postprocedure compression, the use of postprocedure
anticoagulation therapy, or the time interval to the study
allowing for some thrombus resolution or recanalization. It
is interesting that the sheath size seemed to have an inverse
correlation with thrombosis, and I wonder if the authors
have any thoughts about the reason for this.
When we recently reviewed our own database of 1191
patients with acute DVT who had filter placement, 488 of
them had undergone anticoagulation therapy after place-
ment and 639 had not. We had follow-up data for 465
patients, and they showed a very similar 12% incidence
rate of new DVT, which was independent of whether or
not the patient underwent anticoagulation therapy. In
fact, the only positive correlation was found in patients
with cancer with an increased risk of recurrent DVT.
However, the failure of anticoagulation therapy to protect
against DVT in these prothrombotic patients should not
argue against its use where possible because the ability to
prevent further propagation of existing DVT is important
in minimizing the risk of phlegmasia cerulea dolens and in
reducing the severity of the post-thrombotic syndrome.
In bringing this subject to our attention, the authors
have challenged us to reexamine the technical aspects of
filter insertion to reduce this complication. Their sugges-
tion of a trial comparing jugular with femoral insertion is
certainly worth consideration, and I believe that other
innovative approaches, such as using ultrasound scanning
for bedside placement and perhaps eliminating external
compression after sheath removal as suggested by Dr
Kyung Cho in our own radiology department, will add to
the safety and cost effectiveness of filter placement.
Thank you for the opportunity of commenting on this
excellent paper.
Dr John Blebea. Thank you, Dr Greenfield, for your
comments and insightful discussion. Only a minority of all
patients receiving vena caval filters had postoperative
duplex scanning performed and were therefore included in
this report. Although all the surgical patients had such
subsequent scans done routinely, only seven of the 35
patients (20%) had venous studies performed because they
were documented to be symptomatic with leg pain or
swelling. Nonetheless, there is probably a negative selec-
tion bias in such a retrospective study, and the true inci-
dence of postinsertion DVT would best be answered with
a prospective study.
The duration of sheath placement and the extent of
manual compression on the vein were neither measured
nor reported, and their effect on subsequent DVT devel-
opment is unknown. We examined the use of anticoagula-
tion therapy, as reflected by the prothrombin time, the
international normalized ratio, and the partial thrombo-
plastin time, both at the time of the initial filter insertion
and at the follow-up evaluation. In this small group of
patients, there were no significant differences in these val-
ues between patients with and without subsequent DVT
development.
Non-occlusive thrombi were most frequent in the
common femoral and external iliac veins. This suggests
that these thrombi are caused by intimal injury during
sheath insertion, which, for unknown reasons, does not
progress to complete occlusion. The relatively early fol-
low-up venous scans in these patients, and their ultrasonic
characteristics, suggest that these are initial non-occlusive
thrombi rather than chronic recanalized thrombi.
Our finding that smaller diameter filters were not asso-
ciated with a decrease in the incidence of DVT indicates
that other clinical variables are more important risk factors
for later thrombus development. Identifying and modify-
ing such risk factors, or reexamining alternative insertion
sites, remains a challenge for the future.
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